Preeminent IP position gives Sherlock freedom to operate and commercialize across multiple CRISPR business avenues.

The state of play in the field of CRISPR diagnostics has been changing rapidly. Here, Bryan DeChairo, CEO of Sherlock Biosciences, discusses the...

We have added three clinical trials to our comprehensive database of the current CRISPR-based trials for gene-editing therapies and diagnostics. This...

For the first time, the FDA has authorized a CRISPR gene-editing tool - the COVID 19 diagnostic kit developed by Sherlock Biosciences, here CEO Rahul...